Research Article
Abstract
Several cases of
tuberculosis in people with COVID-19 and lung diseases have recently been
reported worldwide, particularly in India. Tuberculosis treatment usually
includes antifungal medications like Posaconazole, Isavuconazole, and
Amphotericin B. Tubercu[1]losis
(TB) is an infection caused by bacteria that usually affect the lungs. These
bacteria, called Mycobacterium tuberculosis, can be passed on to another person
through tiny droplets spread by coughing and sneezing. This present study deals
with identifying a possible alternative to the available antibiotics and
steroids. Potential plant derived com[1]pounds
will be the best possible alternative with negative side effects. Lagerstroemia
spe[1]ciosa
is one such plant that has been proven to possess various bioactive properties.
Hence based on earlier reports, one such compound, undecanoic acid was
considered to be a potential agent against tuberculosis. Molecular docking
analysis was carried out to evaluate the possibility to use these molecules
against tuberculosis. Docking was performed for the identification of ethanolic
extract from Lagerstroemia speciosa seeds on the binding of
tuberculosis-targeted proteins (PDB ID: 7D6V and 1UH9). The molecular docking
score of PDB ID: 7D6V Ethyl 11-bromoundecanoate is -3.18 kcal/mol and
Isavuconazole is -4.52 kcal/mol and PDB ID: 1UH9 Ethyl 11-bromoundecanoate is
-5.264 kcal/mol and Isavucon[1]azole
is -8.69 kcal/mol. All molecules of a binding score (docking score) of more
than -7.0 kcal/mol with the proteins. This suggests a possible potent
alternative source for tubercu[1]losis
through further research.
Keywords
Mycobacterium tuberculosis, COVID 19, lung diseases, Molecular docking, Tuberculosis
Abstract
Several cases of
tuberculosis in people with COVID-19 and lung diseases have recently been
reported worldwide, particularly in India. Tuberculosis treatment usually
includes antifungal medications like Posaconazole, Isavuconazole, and
Amphotericin B. Tubercu[1]losis
(TB) is an infection caused by bacteria that usually affect the lungs. These
bacteria, called Mycobacterium tuberculosis, can be passed on to another person
through tiny droplets spread by coughing and sneezing. This present study deals
with identifying a possible alternative to the available antibiotics and
steroids. Potential plant derived com[1]pounds
will be the best possible alternative with negative side effects. Lagerstroemia
spe[1]ciosa
is one such plant that has been proven to possess various bioactive properties.
Hence based on earlier reports, one such compound, undecanoic acid was
considered to be a potential agent against tuberculosis. Molecular docking
analysis was carried out to evaluate the possibility to use these molecules
against tuberculosis. Docking was performed for the identification of ethanolic
extract from Lagerstroemia speciosa seeds on the binding of
tuberculosis-targeted proteins (PDB ID: 7D6V and 1UH9). The molecular docking
score of PDB ID: 7D6V Ethyl 11-bromoundecanoate is -3.18 kcal/mol and
Isavuconazole is -4.52 kcal/mol and PDB ID: 1UH9 Ethyl 11-bromoundecanoate is
-5.264 kcal/mol and Isavucon[1]azole
is -8.69 kcal/mol. All molecules of a binding score (docking score) of more
than -7.0 kcal/mol with the proteins. This suggests a possible potent
alternative source for tubercu[1]losis
through further research.
Keywords
Mycobacterium tuberculosis, COVID 19, lung diseases, Molecular docking,
Tuberculosis
References
1.
World Health Organization–Fact Sheets
Available online: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
(accessed on 27 October 2022).
2.
Konstantinos A. Testing for
tuberculosis. Aust. Prescr. 2010, 33, 12-18.
3.
Implementing the WHO Stop TB Strategy: A
Handbook for National Tuberculosis Control Programmes. Geneva: World Health
Organization, 2008.
4.
Eurosurveillance editorial team. WHO
publishes Global tuberculosis report 2013. Euro Surveill. 2013, 18(43), 20615.
5.
Madison, B. M. Application of stains in
clinical microbiology. Biotech. Histochem. 2001, 76(3), 119–125.
6.
Parish, T.; Stoker, N. G. Mycobacteria:
bugs and bugbears (two steps forward and one step back). Mol. Biotechnol. 1999,
13 (3), 191–200.
7.
Van Soolingen, D.; Hoogenboezem, T.; de
Haas, P.E.; Hermans, P. W.; Koedam, M. A.; Teppema, K. S. A novel pathogenic
taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of
an exceptional isolate from Afric. Int. J. Syst. Bacteriol. 1997, 47 (4),
1236–45.
8.
Ranaweera, A. Diagnosis and treatment of
disease caused by nontuberculous mycobacteria. This official statement of the
American thoracic society was approved by the board of directors, March 1997.
Medical section of the American lung association. Am. J. Respir. Crit. Care.
Med. 1997, 156, 1–25.
9.
Escalante, P. In the clinic.
Tuberculosis. Ann. Intern. Med. 2009, 151(4), 292.
10.
Special Programme for Research &
Training in Tropical Diseases. Diagnostics for tuberculosis: global demand and
market potential. Geneva: World Health Organization (WHO). 2006, 36.
11.
Tuberculosis: Clinical Diagnosis and
Management of Tuberculosis, and Measures for Its Prevention and Control National
Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice
at NICE (UK). London: National Institute for Health and Clinical Excellence
(UK); 2011 March. National Institute for Health and Clinical Excellence:
Guidance-Clinical guideline 117.
12.
Escalante, P. In the clinic.
Tuberculosis. Ann. Inter. Med. 2009, 150-11.
13.
Jindal, S.K. Textbook of Pulmonary and
Critical Care Medicine. New Delhi: Jaypee Brothers Medical Publishers. 2011, 544.
14.
Bibbins-Domingo, K.; Grossman, D. C.;
Curry, S. J.; Bauman, L.; Davidson, K. W.; Epling, J. W. Screening for Latent
Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation
Statement. JAMA. 2016, 316, 962–9.
15.
Latent Tuberculosis Infection Resources.Division
of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and
TB Prevention, Centers for Disease Control and Prevention, 2021.
16.
Kashangura, R.; Jullien, S.; Garner, P.;
Johnson, S. (Cochrane Infectious Diseases Group). MVA85A vaccine to enhance BCG
for preventing tuberculosis. Cochrane Database Syst. Rev. 2019, 4(4), 012915.
17.
Brennan, P.J.; Nikaido, H. The envelope
of mycobacteria. Ann. Rev. Biochem. 1995, 64, 29–63.
18.
Eduardo, B.; Principe; Aurora, S.; Jose.
Propagation Management of Herbal and Medicinal Plants. Research Information
Series on Ecosystems. 2007.
19.
Tanaka, Y.; Van, K. N. Edible Wild
Plants of Vietnam: The Bountiful Garden. Thailand: Orchid Press. 2007, 90.
20.
Gilman, E. F.; Watson, D. G.; Klein,
R.W.; Koeser, A. K.; Hilbert, D. R.; McLean, D. C. Lagerstroemia speciosa:
Queens Crape Myrtle. Environmental Horticulture Department, UF/IFAS Extension
Series. 2018.
21.
Modi, M.; Goel, T.; Das, T.; Malik, S.;
Suri, S.; Rawat, A. K. S.; Srivastava, S. K.; Tuli, R.; Malhotra, S.; Gupta, S.
K. Ellagic acid & Gallic acid from Lagerstroemia
speciosa L. inhibit HIV-1 infection through inhibition of HIV-1 protease
& reverse transcriptase activity. Indian J. Med. Res. 2013, 137(3), 540-8.
22.
Thakur, R. S.; Devaraj, E. Lagerstroemia
speciosa (L.) Pers. triggers oxidative stress mediated apoptosis via
intrinsic mitochondrial pathway in HepG2 cells. Environ. Toxicol. 2020, 35(11),
1225-1233.
23.
Sharmin, T.; Rahman, M. S.; Mohammadi,
H. Investigation of biological activities of the flowers of Lagerstroemia
speciosa, the Jarul flower of Bangladesh. BMC Complement. Altern. Med.
2018, 6, 18(1), 231.
24.
Mousa, A. M.; El-Sammad, N. M.;
Abdel-Halim, A. H.; Anwar, N.; Khalil, W. K. B.; Nawwar, M.; Hashim, A. N.;
Elsayed, E. A.; Hassan, S. K. Lagerstroemia speciosa (L.) Pers Leaf
Extract Attenuates Lung Tumorigenesis via Alleviating Oxidative Stress,
Inflammation and Apoptosis. Biomolecules. 2019, 12, 9(12), 871.
25.
Andrade, C.; Gomes, N. G. M.;
Duangsrisai, S.; Andrade, P. B.; Pereira, D. M.; Valentão, P. Medicinal plants
utilized in Thai Traditional Medicine for diabetes treatment: Ethno botanical
surveys, scientific evidence and phytochemicals. J. Ethnopharmacol. 2020, 5,
263, 113177.
26.
Amresh, G.; Agarwal, V. K; Rao, C. V.
Self micro emulsifying formulation of Lagerstroemia speciosa against
chemically induced hepatotoxicity. J. Tradit. Complement. Med. 2017, 3, 8(1), 164-169.
27.
Hidayat, I. W. The ecological role of
trees and their interactions in forming the microclimate amenity of
environment. J. Bumi Lestari. 2010, 10(2), 2527-6158.
28.
MOE version–2015.10–Chemical Computing
Group: Montreal, QC, Canada.
29.
Ajayi, E. O.; Sadimenko, A. P.;
Afolayan, A. J. GC-MS evaluation of Cymbopogon citratus (DC) Stapf oil
obtained using modified hydro distillation and microwave extraction methods.
Food Chem. 2016, 209, 262-266.
30.
Junaid, S.; Rakesh, K. N.; Dileep, N.;
Poornima, G.; Kekuda, T. R. P.; Mukunda,
S. Total phenolic content and antioxidant activity of seed extract of Lagerstroemia
speciosa L. Chem. Sci. Trans. 2013, 2(1), 75-80.
31.
Uma, B.; Prabhakar, K.; Rajendran, S.;
Sarayu, Y.L. Studies on GC/MS spectroscopic analysis of some bioactive
antimicrobial compounds from Cinnamomum zeylanicum. J. Med. Plants,
2009, 8,125–131.
32.
Deshpande, S. N.; Kadam, D. G. GCMS
analysis and antibacterial activity of Piper beetle (Linn) leaves
against Streptococcus mutans. Asian J. Pharm. Clin. Res. 2013, 6,
99–101.
33.
Al‐Rubaye, A. F.; Kadhim, M. J.; Hameed,
I. H. Phytochemical profiles of methanolic seeds extract of Cuminum cyminum
using GC‐MS technique. Int. J. Curr. Pharm. Rev. Res. 2017, 8, 114–124.
34.
Joshi, R. K. GC—MS analysis of the
essential oil of Ocimum gratissimum L. growing desolately in South
India. Acta. Chromatogr. 2017, 29, 111–119.
35.
Cai, J.; Lin, P.; Zhu, X.; Su, Q.
Comparative analysis of clary sage (S. sclarea L.) oil volatiles by
GC—FTIR and GC—MS. Food Chem. 2006, 99, 401–407.
36.
Chekki, R. Z.; Snoussi, A.; Hamrouni,
I.; Bouzouita, N. Chemical composition, antibacterial and antioxidant
activities of Tunisian garlic (Allium sativum) essential oil and ethanol
extract. Mediterr. J. Chem. 2014, 3, 947–956.
37.
Martínez, A. L.; González‐Trujano, M. E.;
Pellicer, F.; López‐Muñoz, F. J.; Navarrete, A. Antinociceptive effect and
GC/MS analysis of Rosmarinus officinalis L. essential oil from its
aerial parts. Planta Med. 2009, 75, 508–511.
38.
Hudaib, M.; Speroni, E.; di Pietra, A. M.;
Cavrini, V. GC/MS evaluation of thyme (Thymus vulgaris L.) oil
composition and variations during the vegetative cycle. J. Pharm. Biomed. Anal.
2002, 29, 691–700.
39.
McConkey, B. J.; Sobolev, V.; Edelman,
M. The performance of current methods in ligand-protein docking. Cur. Sci.
2002, 83, 845–855.
40.
Yuan, S.; Chan, H. C.; Hu, Z. Using
PyMOL as a platform for computational drug design. Wiley Interdiscip. Rev.
Comput. Mol. Sci. 2017, 7, 1298.
41.
Hanwell, M. D.; Curtis, D. E.; Lonie, D.
C.; Vandermeersch, T.; Zurek, E.; Hutchison, G. R. Avogadro: An advanced
semantic chemical editor, visualization, and analysis platform. J. Cheminform.
2012, 4. 1-17.
42.
O'Boyle, N. M.; Banck, M.; James, C. A.;
Morle, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: An open chemical
toolbox. J. Cheminform. 2011, 3, 1-4.
43.
Forli, W.; Halliday, S.; Belew, R.;
Olson, A. J. Auto Dock Version 4.2. Citeseer, Princeton, 2012.
44.
DeLano, W. L. PyMOL: An open-source
molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002, 40(1), 82–92
45. Lameh, F.; Baseer, A. Q.; Ashiru, A. G. Comparative molecular docking and molecular-dynamic simulation of wild-type- and mutant carboxylesterase with BTA-hydrolase for enhanced binding to plastic. Eng. Life Sci. 2021, 22(1), 13-29.
46. Dinakarkumar, Y.; Rajabathar, J. R.; Arokiyaraj, S.; Jeyaraj, I.; Anjaneyulu, S. R.; Sandeep, S.; Karthik, C. S.; Appaturi, J. N.; Wilson, L. D. Anti-Methanogenic Effect of Phytochemicals on Methyl-Coenzyme M Reductase-Potential: In Silico and Molecular Docking Studies for Environmental Protection. Micro machines (Basel). 2021, 12(11), 1425.
This work is licensed under the
Creative Commons Attribution
4.0
License (CC BY-NC 4.0).
Abstract
Several cases of
tuberculosis in people with COVID-19 and lung diseases have recently been
reported worldwide, particularly in India. Tuberculosis treatment usually
includes antifungal medications like Posaconazole, Isavuconazole, and
Amphotericin B. Tubercu[1]losis
(TB) is an infection caused by bacteria that usually affect the lungs. These
bacteria, called Mycobacterium tuberculosis, can be passed on to another person
through tiny droplets spread by coughing and sneezing. This present study deals
with identifying a possible alternative to the available antibiotics and
steroids. Potential plant derived com[1]pounds
will be the best possible alternative with negative side effects. Lagerstroemia
spe[1]ciosa
is one such plant that has been proven to possess various bioactive properties.
Hence based on earlier reports, one such compound, undecanoic acid was
considered to be a potential agent against tuberculosis. Molecular docking
analysis was carried out to evaluate the possibility to use these molecules
against tuberculosis. Docking was performed for the identification of ethanolic
extract from Lagerstroemia speciosa seeds on the binding of
tuberculosis-targeted proteins (PDB ID: 7D6V and 1UH9). The molecular docking
score of PDB ID: 7D6V Ethyl 11-bromoundecanoate is -3.18 kcal/mol and
Isavuconazole is -4.52 kcal/mol and PDB ID: 1UH9 Ethyl 11-bromoundecanoate is
-5.264 kcal/mol and Isavucon[1]azole
is -8.69 kcal/mol. All molecules of a binding score (docking score) of more
than -7.0 kcal/mol with the proteins. This suggests a possible potent
alternative source for tubercu[1]losis
through further research.
Abstract Keywords
Mycobacterium tuberculosis, COVID 19, lung diseases, Molecular docking, Tuberculosis
This work is licensed under the
Creative Commons Attribution
4.0
License (CC BY-NC 4.0).
This work is licensed under the
Creative Commons Attribution 4.0
License.(CC BY-NC 4.0).